As the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function relationships, aggregation, microheterogenicity, and glycosylation, and more, helps minimise development risks.
Rentschler Biopharma expands U.S. footprint
OpinionPrior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s SVP Global BD Federico Pollano about the CDMO’s expertise in DuoBody® molecules production and the expansion of the CDMO’s U.S. production site in Milford.
A plucked chicken named Horizon Europe
Latest NewsAccording to current information, the European Research Framework Programme "Horizon Europe" is likely to be among the indirect victims of the Corona pandemic: A large part of the funds earmarked will now go to the € 750 billion rescue fund.
Defining the bioprocess is early quality control
Latest NewsAs the process determines the product, product characteristics of biological drugs need to be analysed thoroughly right from the beginning of the drug development process. Early understanding of structure-function relationships, aggregation, microheterogenicity, and glycosylation, and more, helps minimise development risks.
Quantro: Seed capital by Evotec and Boehringer
Latest NewsGermany’s Evotec SE and Boehringer Ingelheim Venture Fund have acquired equal minority stakes in Quantro Therapeutics GmbH, a recently established research-based biotech company based in Vienna. Evotec also entered into a comprehensive partnership with the Austrian start-up, that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programmes in cancer and other diseases. The Germans will provide hit identification services for Quantro’s proprietary anti-tumour projects.
Sourcing reference products
Latest NewsA biosimilar is a copy version of an approved, original biological medice whose patent protection has expired. The development strategies for biosimilar product and a new biological entity (NBE) differ in many ways.
European Greens fight over a revision of EU GMO law
BackgroundAn impulse paper of a green splinter group has ignited a storm in the water glass. Like industry and science lobbyists, the renegades are calling for changes to the EU’s legal GMO framework.
BioProfile FLEX2
ProductsBioProfile FLEX2 combines Nova’s groundbreaking MicroSensor Card technology with optical measurement and freezing point osmometry for an automated and comprehensive cell culture analyzer that eliminates chemistry sensor maintenance, increases analyzer speed, and reduces sample volume.
Go 3D with BIOFLOAT
ProductsBIOFLOAT coatings from faCellitate provide a highly defined, fully inert cell- and protein-repellent surface.
Targeting coronaviruses
Latest NewsViennese APEIRON Biologics AG raised €17.5m to expand ongoing Phase II trials of its
coronavirus-specific drug candidate APN01 in Europe to the US and Russia. The recombinant angiotensin-converting enzyme 2 (rhACE2) mimics the receptor on the human cells that coronaviruses are using to infect these cell. Preclinical and clinical data demonstrate that APN01 is well-tolerated and can stop the overshooting host immune responses that are triggered by virus proliferation.
The road to recovery goes via vaccines and antibodies
OpinionIf reopening the economy after the prolonged shutdown was the end of the beginning, then the successful development of vaccines and therapeutic antibodies has the potential to be the beginning of the end.